Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | BCL2 | P10415 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tirapazamine SCHEMBL29360622 | 1.00 | CA12 (0.39) | CA12CA1CA2CA9BCL2 | |
| Tirapazamine SCHEMBL28865429 | 0.85 | CA12 (0.33) | CA12CA1CA2CA9BCL2 | |
| Tirapazamine SCHEMBL28856314 | 0.83 | CA12 (0.32) | CA12CA1CA2CA9BCL2 | |
| SCHEMBL19235741 | 0.79 | MEN1 (0.38) | BCL2ATMMEN1POLBCASP6 | |
| SCHEMBL1695948 | 0.79 | CA12 (0.32) | CA12CA1CA2CA9ATM | |
| SCHEMBL15024662 | 0.75 | BACE1 (0.32) | MEN1KMT2A | |
| SCHEMBL2775458 | 0.75 | TSHR (0.33) | — | |
| SCHEMBL15008539 | 0.74 | ATM (0.37) | CA12CA1CA2CA9BCL2 | |
| SCHEMBL13084389 | 0.74 | ATM (0.37) | CA12CA1CA2CA9BCL2 | |
| SCHEMBL6084998 | 0.74 | MEN1 (0.45) | CA12CA1CA2CA9BCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 21131 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| CN-121466351-B | Composite nano gel and preparation method and application thereof | 华中科技大学同济医学院附属协和医院 | 2026-05-15 | — | — | CN | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| EP-4732908-A2 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | Biomed Valley Discoveries, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| US-20260091119-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF GLIOMA | CELLIS AG (CH) | 2026-04-02 | — | — | US | claimed |
| US-12570704-B2 | Functionally modified maytansinoids and compositions and methods of use thereof | University of Georgie Research Foundation, Inc. (US) | 2026-03-10 | — | — | US | claimed |
| EP-4043017-B1 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4676551-A1 | RADIATION SPACER HYDROGELS, METHODS OF FORMING, AND METHODS OF USE | Clearstream Technologies Limited (IE) | 2026-01-14 | — | — | EP | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| US-20250367471-A1 | PERFUSION MODULATED TUMOR DOSE SCULPTING WITH SINGLE DOSE RADIOTHERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-12-04 | — | — | US | claimed |
| WO-1997011699-A1 | 1,2,4-BENZOTRIAZINE OXIDES FORMULATIONS | SANOFI WINTHROP INC. (US) | 1997-04-03 | — | — | WO | claimed |
| US-5616584-A | ADMINISTERING A SENSITIZER PRIOR ANTITUMOR RADIATION THERAPY | SRI INTERNATIONAL (US) | 1997-04-01 | — | — | US | claimed |
| US-5484612-A | Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1996-01-16 | — | — | US | claimed |
| EP-0649658-A1 | Method of tumor treatment | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1995-04-26 | — | — | EP | claimed |
| US-5399363-A | IV administration for insoluble medicaments | EASTMAN KODAK COMPANY (US) | 1995-03-21 | — | — | US | claimed |
| EP-0577215-A1 | Surface modified anticancer nanoparticles | NanoSystems L.L.C. (US) | 1994-01-05 | — | — | EP | claimed |
| EP-0478545-A4 | 1,2,4-BENZOTRIAZINE OXIDES AS RADIOSENSITIZERS AND SELECTIVE CYTOTOXIC AGENTS | STANFORD RES INST INT (US) | 1992-08-05 | — | — | EP | claimed |
| EP-0478545-A1 | 1,2,4-BENZOTRIAZINE OXIDES AS RADIOSENSITIZERS AND SELECTIVE CYTOTOXIC AGENTS | SRI INTERNATIONAL (US) | 1992-04-08 | — | — | EP | claimed |
| WO-1991004028-A1 | 1,2,4-BENZOTRIAZINE OXIDES AS RADIOSENSITIZERS AND SELECTIVE CYTOTOXIC AGENTS | SRI INTERNATIONAL (US) | 1991-04-04 | — | — | WO | claimed |
| US-4102840-A | FORMALDEHYDE, ETHERIFICATION, CREASE RESISTANCE, SHRINK RESISTANCE | CIBA-GEIGY CORPORATION (US) | 1978-07-25 | — | — | US | claimed |